Fact-checked by Grok 2 weeks ago

Filoviridae

Filoviridae is a family of enveloped viruses classified in the order Mononegavirales, featuring non-segmented, linear, negative-sense, single-stranded RNA genomes of approximately 13–21 kb that encode typically seven structural proteins, with virions exhibiting filamentous morphology, often 80 nm in diameter and varying from hundreds of nanometers to over 14,000 nm in length. The family encompasses multiple genera, including Ebolavirus, Marburgvirus, Cuevavirus, Diamlovirus, and several recently established ones such as Chenyangvirus and Pandemovirus, primarily infecting mammals, reptiles, and fish, though human-pathogenic species like Zaire ebolavirus and Marburg marburgvirus cause acute viral hemorrhagic fevers characterized by high case-fatality rates exceeding 50% in many outbreaks. Genomes of filoviruses follow a conserved 3′–NP–VP35–VP40–GP–VP30–VP24–L–5′ organization, where forms the nucleocapsid, VP35 and comprise the RNA-dependent RNA polymerase complex for transcription and replication, VP40 drives , mediates entry, and accessory proteins like VP24 and VP30 modulate host responses. Replication occurs in the host , initiating with primary transcription to produce mRNAs and proteins, followed by synthesis of full-length antigenomic RNA templates for progeny genomes, with virions assembling at the plasma membrane via matrix protein-directed envelopment. Filoviruses were first identified in 1967 during outbreaks of hemorrhagic fever among laboratory workers in Marburg and Frankfurt, Germany, linked to African green monkey tissues, with Marburg marburgvirus isolated shortly thereafter; Ebolavirus emerged in 1976 near the Ebola River in Sudan and the Democratic Republic of Congo. Subsequent discoveries expanded the family, revealing reservoir hosts like fruit bats and highlighting zoonotic spillover risks, while advances in molecular phylogeny trace divergences to thousands of years ago, underscoring evolutionary stability amid sporadic, severe epidemics.

Nomenclature and Taxonomy

Etymology and historical use

The name Filoviridae derives from the Latin filum, meaning "thread," reflecting the distinctive filamentous or thread-like morphology of the enveloped virions produced by family members, which often appear as elongated, flexible rods or filaments under electron microscopy. The taxonomic family Filoviridae was formally defined in 1982 by the International Committee on Taxonomy of Viruses (ICTV) to accommodate viruses with these shared morphological traits, initially grouping the genera Marburgvirus and Ebolavirus based on their negative-sense, single-stranded RNA genomes and biological properties distinct from related rhabdoviruses. Prior to this, isolates like Marburg virus—discovered on August 1, 1967, during an outbreak among laboratory workers in Marburg, Germany, exposed to imported African green monkeys—were provisionally classified within the Rhabdoviridae family due to superficial virion similarities, though genetic and replicative differences prompted reevaluation. Ebolavirus emerged in 1976 with simultaneous outbreaks near the in (now ) and , leading to proposals for a unified filovirus by the late 1970s, as discussed at symposia including one in in 1977; the 1982 establishment marked the first dedicated family, with subsequent revisions expanding it to include additional genera like Cuevavirus (proposed 2011) and Diamlovirus amid discoveries of bat-associated filoviruses. The has evolved to emphasize mononegaviral membership, but the core "filo-" persists to denote the conserved thread-like particle forms essential for criteria.

Classification criteria and genera

The classification of viruses within the family Filoviridae relies primarily on phylogenetic relationships inferred from complete sequences, with genus demarcation determined using the pairwise sequence comparison (PASC) tool applied to coding-complete genomes. This sequence-based approach identifies distinct clades separated by identity thresholds typically below 55-60% across the , reflecting evolutionary divergence while accounting for shared mononegaviral traits such as non-segmented, negative-sense genomes encoding conserved proteins (e.g., , ). Morphological uniformity—enveloped, filamentous virions 800-1400 nm long—and replication strategies provide supplementary criteria but do not distinguish genera, as these features are conserved across the family. Biological properties, including host range (mammals, reptiles, fish) and pathogenicity, inform but do not override molecular data in taxonomic decisions by the International Committee on Taxonomy of Viruses (ICTV). As of the 2024 ICTV taxonomy, Filoviridae comprises seven genera: Cuevavirus, Dianlovirus, Oblavirus, Orthoebolavirus, Orthomarburgvirus, Striavirus, and Tapjovirus. The genera Orthoebolavirus (renamed from Ebolavirus in 2023) and Orthomarburgvirus (renamed from Marburgvirus) include the most studied human-pathogenic species, such as Orthoebolavirus zairense (Ebola virus) and Orthomarburgvirus marburgense (Marburg virus), distinguished by <50% genome-wide amino acid identity from other genera. Less-characterized genera like Cuevavirus (e.g., Lloviu cuevavirus) and Tapjovirus (e.g., Měnglà tapjovirus) were established based on sequences from bat reservoirs, showing 40-55% divergence from orthoebolaviruses and unique accessory genes. Striavirus and Dianlovirus represent reptile- and fish-associated lineages, respectively, with genomes encoding genus-specific proteins that alter replication efficiency in non-native hosts. Oblavirus encompasses provisional taxa pending full characterization.
GenusExample SpeciesKey Distinguishing FeaturesPrimary Hosts
CuevavirusLloviu cuevavirusAccessory proteins VP24-like; ~45% aa identity to orthoebolavirusesBats
DianlovirusDianlo virusFish-adapted genome adaptationsFish
OblavirusObla virusProvisional; limited sequence dataUnknown
OrthoebolavirusOrthoebolavirus zairenseSeven species; sGP gene editing; human hemorrhagic feverPrimates, bats
OrthomarburgvirusOrthomarburgvirus marburgenseFour species; no sGP; similar pathogenicityPrimates, bats
StriavirusStriavirus striatusReptile-specific genes; divergent polymeraseReptiles
TapjovirusMěnglà tapjovirusBat-derived; unique VP35 motifsBats
This structure reflects ongoing refinements, with PASC ensuring objective delineation amid expanding metagenomic data from diverse reservoirs.

Species diversity and recent discoveries

The family Filoviridae encompasses seven genera: Cuevavirus, Dianlovirus, Oblavirus, Orthoebolavirus, Orthomarburgvirus, Striavirus, and Tapjovirus, comprising a total of approximately 12 recognized species as delineated by the International Committee on Taxonomy of Viruses (ICTV) in its 2024 classification. The genera vary in host specificity, geographic distribution, and genomic features, with Orthoebolavirus and Orthomarburgvirus primarily associated with mammalian hosts in Africa and capable of causing severe hemorrhagic fever in humans, while others like Cuevavirus and Dianlovirus have been identified in bats from Europe and Asia, respectively, without confirmed human pathogenicity to date. Orthoebolavirus includes six species—Zaire ebolavirus, Sudan ebolavirus, Taï Forest ebolavirus, Bundibugyo ebolavirus, Reston ebolavirus, and Bombali ebolavirus—distinguished by serological and genetic differences leading to their separate classification since 2010. Orthomarburgvirus consists of two species: Marburg marburgvirus and Ravn virus, both originating from African reservoirs. The remaining genera each harbor one or few species, such as Lloviu cuevavirus in Cuevavirus (isolated from Spanish bats) and Měnglà dianlovirus in Dianlovirus (from Chinese bats), reflecting broader ecological diversity extending to reptilian and piscine hosts in some lineages. Recent discoveries have expanded Filoviridae's known diversity through metagenomic surveillance of wildlife, particularly bats, revealing non-pathogenic or divergent members that inform evolutionary and spillover risk assessments. In 2011, Lloviu cuevavirus was identified via deep sequencing of dead Schreiber's bats in a Spanish cave, marking the first filovirus outside Africa and prompting genus establishment based on phylogenetic divergence exceeding 50% from ebolaviruses. Měnglà dianlovirus, discovered in 2015-2016 from Rousettus bats in Yunnan Province, China, introduced the Dianlovirus genus due to its unique gene arrangement and Asian host association, with sequence data indicating isolation from human-infecting filoviruses. Bombali ebolavirus, proposed as a new Orthoebolavirus species in 2019, was detected in Angolan free-tailed bats in Sierra Leone, representing the most basal ebolavirus lineage identified to date and raising concerns for potential zoonotic emergence despite lacking isolates or direct human cases. These findings, primarily from genomic sequences without cultured isolates, underscore gaps in virological understanding, as no new species have been formally ratified by ICTV between 2020 and 2025, though ongoing bat surveillance has refined host associations without yielding additional taxa.

Virological Characteristics

Genome structure and virion morphology

The genome of filoviruses consists of a single, linear, non-segmented, negative-sense RNA molecule, typically 18–19 kb in length, which is noninfectious and lacks polyadenylation. This genome encodes seven canonical open reading frames arranged in the conserved order 3′--VP35-VP40-GP-VP30-VP24-L-5′, producing proteins including the , polymerase cofactor (VP35), matrix protein (VP40), surface glycoprotein (GP), transcription activator (VP30), accessory protein (VP24), and RNA-dependent RNA polymerase (L). Genome lengths vary slightly among genera, ranging from approximately 15 to 19 kb, with some species exhibiting additional open reading frames or gene overlaps. Filovirus virions are enveloped particles exhibiting filamentous morphology, with a uniform diameter of about 80 nm and lengths ranging from 790 nm to over 14,000 nm, though typical forms measure 800–1,200 nm. The envelope, derived from host cell membranes, is studded with trimeric glycoprotein spikes approximately 10 nm long, while the internal helical nucleocapsid, formed by the ribonucleoprotein complex, maintains the genome's rod-like structure. Virions display pleomorphism, appearing not only as straight filaments or bacilliform shapes but also in branched, toroidal, U-, or 6-shaped configurations, with rare spherical forms observed under certain conditions.

Replication and life cycle

Filoviruses initiate infection by attaching to host cell surfaces via their surface glycoprotein (GP), which binds to various attachment factors such as TIM-1, C-type lectins, or integrins, followed by macropinocytosis or clathrin-mediated endocytosis for entry. Within endosomes, GP undergoes proteolytic cleavage by cathepsins, exposing a receptor-binding domain that interacts with the cholesterol transporter NPC1 to trigger membrane fusion and release of the ribonucleoprotein complex into the cytoplasm. Upon release, the negative-sense, single-stranded RNA genome, encapsidated by nucleoprotein (NP) and associated with viral polymerase (L) and VP35, serves as a template for primary transcription by the viral RNA-dependent RNA polymerase complex, producing monocistronic mRNAs capped at the 5' end and polyadenylated at the 3' end via a gene-end/leader sequence mechanism. These mRNAs are translated into viral proteins, including nucleoprotein, VP35 (phosphoprotein and interferon antagonist), VP40 (matrix protein), GP (envelope glycoprotein), VP24 (minor matrix and interferon antagonist), and L (polymerase). Initial translation supports the switch to replication, where the polymerase synthesizes full-length positive-sense antigenomic RNA, which is encapsidated and serves as a template for new negative-sense genomic RNAs. Replication occurs primarily in cytoplasmic inclusion bodies formed by VP35 and NP, which concentrate viral components and shield replication from host defenses. Secondary mRNA transcription from progeny genomes amplifies protein synthesis, enabling nucleocapsid assembly where genomic RNA is encapsidated by NP, with VP35 and VP24 facilitating polymerase recruitment. VP40 drives matrix formation, recruiting nucleocapsids to the plasma membrane, where they associate with VP40-induced lipid rafts; budding occurs as virions acquire the host-derived envelope studded with GP trimers, with VP40 and sequence motifs like PTAP/YxxL exploiting ESCRT machinery for release. This asynchronous cycle allows continuous progeny production, with filoviruses producing thousands of virions per infected cell over 24-72 hours post-infection.

Evolutionary History

Phylogenetic relationships

The family Filoviridae forms a monophyletic clade within the order Mononegavirales, with phylogenetic relationships primarily inferred from maximum-likelihood and Bayesian analyses of complete genome sequences, focusing on conserved regions such as the large RNA-dependent RNA polymerase (L) gene. These analyses reveal nine genera divided by host associations: piscine (Oblavirus, Striavirus, Thamnovirus), reptilian (Tapjovirus), and mammalian (Cuevavirus, Dianlovirus, Orthoebolavirus, Orthomarburgvirus). Piscine genera (Striavirus and Thamnovirus) cluster together in a distinct basal clade, reflecting their association with fish hosts in the East China Sea, while Oblavirus (Oberland virus) represents a separate piscine lineage. Reptilian Tapjovirus (Tapajós virus) branches independently, indicating early divergence linked to amphibian and reptile hosts. Among mammalian genera, Dianlovirus (Měnglà virus, identified in Chinese fruit bats) occupies a basal position, followed by Cuevavirus (Lloviu virus, from European bats), which is phylogenetically equidistant from the human-pathogenic clade but branches prior to it. The genera Orthoebolavirus (six species, including Ebola virus) and Orthomarburgvirus (Marburg virus species) form a tightly clustered sister clade, supported by shared genomic architecture and nucleotide identities exceeding 50% in core genes, with their most recent common ancestor estimated around 10-20 million years ago based on coalescent models of 97 whole-genome sequences. Within Orthoebolavirus, species like Zaire ebolavirus diverge from a common ancestor shared with Taï Forest and Bundibugyo ebolaviruses, while Reston ebolavirus shows greater genetic distance. This structure underscores expanded diversity beyond traditional ebolaviruses and marburgviruses, with recent discoveries (e.g., Dianlovirus in 2019, updated taxonomy in 2024) revealing ancient filoviral groups through paleoviral integrations and sequence divergences.

Paleovirology and ancient origins

Paleovirology examines ancient viral integrations, known as endogenous viral elements (EVEs), which record past infections in host germline genomes. For Filoviridae, these non-retroviral RNA viruses rarely integrate due to lacking reverse transcriptase, yet filovirus-like EVEs (EFLs or paleoviruses) have been identified in diverse vertebrate genomes, indicating recurrent ancient endogenization events possibly mediated by host LINE-1 retrotransposons. These elements, primarily preserving nucleoprotein (NP) and VP35 genes, challenge prior estimates of recent filovirus origins (e.g., under 10,000 years) and support a deep evolutionary history spanning millions of years. EFLs have been detected across mammals, including rodents (e.g., mice, rats, hamsters, voles, spalacids), bats ( and species), shrews, tenrecs, marsupials (e.g., opossums), and even fish, with over 500 sequences identified in a 2024 analysis. Specific integrations include orthologous NP-like elements in rat and mouse genomes, flanked by LINE-1 repeats, confirming pre-speciation events around 12-24 million years ago (mya). VP35-like genes in bats show intact open reading frames (ORFs) under purifying selection at approximately 25 sites, maintained for at least 13.4 mya, while NP-like elements predate bat genus divergences over 25 mya. Phylogenetic clustering places these EVEs basal to or nested with modern filoviruses within , forming four ancient clades (HUJV-like, XILV-like, TAPV-like, MARV-like), with extant viruses like grouping amid paleoviruses. Age estimates from EVE orthology and host phylogenies place filovirus-mammal associations in the Miocene Epoch (23-5 mya), with rodent VP35 fossils indicating insertions over 16-23 mya, predating Ebola-Marburg divergence. Deeper traces in fish genomes suggest origins exceeding 400 mya, though mammalian integrations cluster around 28 mya for certain NP-like elements. These findings refute molecular clock models yielding unrealistically young ages, attributing discrepancies to purifying selection obscuring divergence times. Some EFLs retain functionality, such as a rodent VP35-like protein that inhibits replication by binding VP35 and disrupting polymerase complex formation, hinting at co-option for antiviral defense. This selective maintenance across eutherian lineages implies ancient host-virus arms races, potentially shaping filovirus reservoirs and zoonotic potential, with implications for identifying evolutionary constraints on pathogenicity.

Ecology and Transmission

Natural reservoirs and hosts

Bats, particularly species within the family Pteropodidae, are the primary natural reservoirs for filoviruses, maintaining persistent infections without overt clinical disease. For marburgviruses, the Egyptian rousette bat (Rousettus aegyptiacus) has been established as the reservoir through repeated isolation of infectious virus, detection of viral RNA via PCR, and serological evidence of antibodies in wild populations across sub-Saharan Africa, with bats shedding virus in saliva, urine, and feces. Experimental infections confirm asymptomatic carriage and transmission within bat colonies, supporting their role in natural maintenance and spillover events linked to human outbreaks near roosts. Ebolaviruses are similarly associated with fruit bats, with serological and molecular evidence (antibodies and viral RNA fragments) detected in species such as Hypsignathus monstrosus, Epomops franqueti, and Myonycteris torquata in Central and West Africa, correlating spatially and temporally with outbreak origins. However, unlike marburgviruses, no live ebolavirus has been isolated from bats, and reviews indicate fruit bats may not be the sole or primary reservoir, as detection rates remain low and experimental models show variable susceptibility. Other filoviruses, including Lloviu virus, have been linked to insectivorous bats like Miniopterus schreibersii in Europe via isolation and sequencing from tissues. Non-human primates, such as gorillas and chimpanzees, serve as amplifying or dead-end hosts rather than reservoirs, succumbing to severe disease upon infection without sustaining transmission cycles in nature. Humans are incidental hosts, with no evidence of sustained reservoir competence. Zoonotic spillovers typically occur through direct contact with bat excreta, roost environments, or bushmeat handling, underscoring bats' ecological role in filovirus ecology.

Zoonotic spillover mechanisms

Filoviruses, including members of the genera Ebolavirus and Marburgvirus, are believed to spill over into humans primarily from bat reservoirs through direct contact with infected animals or their excreta, such as urine, feces, or saliva containing viable virus. Egyptian rousette bats (Rousettus aegyptiacus) serve as the natural reservoir for , with zoonotic transmission documented in cases involving human entry into bat roosts, particularly during mining or agricultural activities that disturb guano-laden caves; for instance, the 1967 Marburg outbreak in Germany traced to infected monkeys imported from Uganda, but subsequent African cases linked miners to aerosolized or contact exposure in Rousettus colonies. Transmission risk elevates during biannual bat reproductive cycles, when juvenile infection rates peak and shedding increases, facilitating environmental contamination. For Ebola viruses, fruit bats of genera such as and are prime suspects as reservoirs, based on serological and PCR evidence of asymptomatic infection, though experimental confirmation of sustained transmission cycles remains incomplete; spillover likely involves intermediate amplification in primates like gorillas or duikers, hunted as bushmeat, where virus persists in tissues and fluids during handling or consumption. The 1994 Côte d'Ivoire outbreak, for example, implicated a chimpanzee carcass exposing hunters to contaminated blood, initiating human cases. Aerosol transmission from bat guano or oral-fecal routes in overlapping habitats may contribute, but direct fluid contact predominates in traced index cases. Habitat encroachment via deforestation and population expansion heightens spillover probability by increasing human-wildlife interfaces; predictive models correlate forest loss with emergence, estimating annual spillover risk in Central Africa tied to bat birthing pulses and meteorologic stressors amplifying shedding. Most outbreaks stem from singular spillover events, underscoring the rarity of successful cross-species adaptation without subsequent human-to-human chains. Serological surveys in bat-exposed human populations reveal prior undetected spillovers, suggesting underreporting of low-virulence exposures.

Human-to-human transmission dynamics

Human-to-human transmission of filoviruses, such as those causing Ebola virus disease (EVD) and Marburg virus disease (MVD), occurs primarily through direct contact with the blood or bodily fluids—including vomit, feces, urine, saliva, sweat, and semen—of symptomatic infected individuals, typically requiring breaches in skin or mucous membranes. This mode accounts for the amplification of outbreaks following initial zoonotic spillovers, with secondary transmission chains sustained by close interpersonal contact in households, healthcare settings, or during funeral rituals involving manipulation of corpses. Evidence from multiple outbreaks indicates no sustained airborne transmission in natural human settings, though laboratory experiments have demonstrated aerosol infectivity under artificial conditions with high viral loads. Transmission risk escalates with the severity of symptoms and viral shedding, which peaks during the acute phase of illness, often rendering asymptomatic or pre-symptomatic individuals low-risk for onward spread, as documented in contact-tracing studies from the 2013–2016 West African epidemic where over 28,000 cases were linked to symptomatic contacts. Nosocomial spread is a significant driver, with healthcare workers facing elevated risks absent personal protective equipment (PPE); for instance, during early outbreaks, up to 10–20% of cases were healthcare-associated due to inadequate barrier precautions. Similarly, in outbreaks, such as the 2023 cluster in Equatorial Guinea, human-to-human spread via contaminated fomites or direct fluid exposure amplified cases beyond the index zoonotic event. Post-recovery persistence in bodily fluids enables rare but documented long-term transmission routes, particularly sexual, with Ebola virus RNA detectable in semen for up to 12 months or longer in survivors, leading to confirmed reintroductions like the 2018 Guinea flare-up from a survivor's relapse. Basic reproduction numbers (R0) for uncontrolled filovirus outbreaks range from 1.5 to 2.5, reflecting moderate transmissibility dependent on cultural practices and response measures, as modeled from EVD data where household secondary attack rates reached 20–80% without isolation. Effective containment relies on breaking these chains through contact tracing, PPE, and safe burial protocols, which reduced R0 below 1 in later phases of major epidemics.

Diseases and Pathogenesis

Clinical manifestations of key filoviruses

The clinical manifestations of infections caused by pathogenic filoviruses, primarily orthoebolaviruses (such as Zaire ebolavirus and Sudan ebolavirus) and orthomarburgviruses (Marburg marburgvirus), typically present as acute viral hemorrhagic fevers with high case fatality rates. The incubation period ranges from 2 to 21 days, averaging 8 to 10 days for Ebola virus disease (EVD) and 5 to 10 days for Marburg virus disease (MVD). Initial prodromal symptoms are nonspecific and resemble other febrile illnesses, including fever (often >38.3°C), chills, severe , , , , and , occurring in over 90% of cases. These early "dry" symptoms reflect and immune activation but lack features, complicating from , typhoid, or other tropical infections. Progression to the gastrointestinal phase, usually within 3 to 5 days, involves profuse , watery , , and anorexia, leading to rapid and imbalances. A appears in 25-50% of EVD cases and up to 80% of MVD cases, often centripetal and non-pruritic, emerging around day 5. Conjunctival injection, , and are common, with relative despite fever noted in some patients. For , the most virulent , symptoms escalate to hemorrhagic in 10-50% of cases, manifesting as petechiae, ecchymoses, mucosal bleeding (e.g., epistaxis, , ), and . infections follow a similar but with reportedly less frequent overt hemorrhage and slightly lower in historical outbreaks, though gastrointestinal symptoms remain dominant. In the terminal phase, multi-organ dysfunction ensues, characterized by , , hepatic necrosis, (manifesting as , seizures, or coma), and secondary bacterial infections. , , and hiccups signal impending or mediastinal involvement. MVD shares these features but may exhibit more prominent oropharyngeal symptoms and a higher incidence of early , with hemorrhagic manifestations in up to 80% of fatal cases. Survivors often experience post-acute sequelae, including arthralgias, , , and psychosocial effects, persisting for months. Case progression is driven by and endothelial damage, with correlating to severity.

Pathogenic mechanisms

Filoviruses, such as Ebola virus (EBOV) and (MARV), initiate infection by attaching to host cells via their surface (), which facilitates entry through involving proteins like NPC1 and TIM-1. Primary target cells include monocytes, macrophages, and dendritic cells (DCs), where viral replication occurs rapidly, often within hours of entry. This early tropism disrupts and impairs DC maturation, leading to suppressed adaptive immune responses and evasion of type I interferon (IFN) signaling through viral proteins like VP35 and VP24. The viruses induce a dysregulated characterized by initial suppression followed by a hyperinflammatory state. of immune cells triggers massive release, including TNF-α, IL-6, and IL-8, culminating in a "" that promotes endothelial cell activation and dysfunction. Endothelial directly contributes to , as GP-mediated and soluble GP shedding exacerbate barrier breakdown, leading to , hypovolemic shock, and hemorrhage. In parallel, bystander lymphocyte , driven by inflammatory mediators rather than direct , depletes + and + T cells, further compromising immunity. Liver involvement is prominent, with causing hepatocellular and impaired protein synthesis, including clotting factors. Hemostatic abnormalities arise from (DIC), marked by , fibrin deposition, and consumption of coagulation factors, resulting from endothelial damage and procoagulant microparticle release. These mechanisms collectively drive multi-organ failure, with MARV showing similar patterns to EBOV but potentially less pronounced hemorrhage due to differences in GP cleavage and profiles. While animal models like nonhuman primates recapitulate these processes, human data from outbreaks confirm the centrality of immune dysregulation and vascular collapse in lethality.

Case fatality rates and variability

Case fatality rates (CFRs) for diseases caused by pathogenic filoviruses, primarily members of the and genera, typically range from 25% to 90%, with averages around 50% across historical outbreaks. (EBOV), responsible for the majority of virus disease (EVD) cases, exhibits the highest , with a meta-analyzed CFR of 66.6% (95% CI: 55.9–76.8%) from 1976 to 2022 across 42 outbreaks in 16 countries. follows at 48.5% (95% CI: 38.6–58.4%), while Bundibugyo ebolavirus shows lower rates near 40%. Marburgviruses display similar variability, with CFRs from 24% to 88%, often averaging 50–70% in untreated cases. A of filovirus outbreaks underscores this range, attributing differences partly to strain-specific .
Virus SpeciesPooled CFR (%)Range in Outbreaks (%)Key Reference
Zaire ebolavirus66.625–90Meta-analysis, 1976–2022
48.540–70Historical outbreaks
Marburg marburgvirus~5024–88WHO data, multiple outbreaks
CFR variability arises from viral, host, and environmental factors. Strain differences drive baseline lethality; for instance, EBOV induces more severe endothelial damage and cytokine storms than less virulent species like Reston ebolavirus, which rarely causes human fatalities. Host factors include age, nutritional status, co-infections (e.g., or ), and genetic resistance, with younger patients and those receiving fluids/electrolytes showing improved survival. Epidemiological influences are critical: small outbreaks often report inflated CFRs (up to 90%) due to under-detection of mild cases, whereas large epidemics like West Africa's 2014–2016 EBOV outbreak (28,616 cases) yielded a lower 39.5% CFR from better ascertainment and supportive care. Recent interventions, such as and monoclonal antibodies in Rwanda's 2024 outbreak, reduced CFR to 23% (15 deaths among 66 cases), highlighting management efficacy. In field settings, CFR estimates can be biased by diagnostic delays and incomplete reporting; meta-analyses adjust for this by incorporating confirmed cases only, revealing consistent high lethality without modern therapeutics. Non-human primates exhibit near-100% CFRs in experimental infections, suggesting human variability partly reflects partial immunity or milder strains in some spillovers. Overall, while filovirus CFRs remain among the highest for hemorrhagic fevers, advances in rapid diagnostics and care have demonstrably lowered rates in contained outbreaks.

Historical Context and Epidemiology

Discovery and early outbreaks

The , the first identified member of the Filoviridae family, emerged in simultaneous outbreaks in August 1967 among laboratory workers in and , , and , (now ). The infections were linked to handling organs and tissues from African green monkeys ( spp.) imported from for research and production, with no evidence of human-to-human transmission beyond secondary contacts in the initial clusters. A total of 31 primary and secondary cases occurred, resulting in 7 deaths (23% case-fatality rate), characterized by hemorrhagic fever symptoms including fever, rash, gastrointestinal distress, and in severe cases, multi-organ failure. Electron microscopy of patient samples revealed the virus's distinctive filamentous, thread-like —up to 14,000 long and variable in shape—distinguishing it from known pathogens and prompting its initial classification within the family before recognition as a novel entity. Isolation and serological studies confirmed the zoonotic spillover from hosts, with no prior cases documented despite serological surveys suggesting possible undetected circulation in . The outbreaks prompted early international collaboration, including autopsies and virological analysis at institutions like the , establishing protocols for handling high-containment pathogens. Nearly a decade later, in 1976, two independent outbreaks of a morphologically similar hemorrhagic fever led to the discovery of virus, expanding the known filovirus diversity. The first, in southern near Nzara and Maridi from June to November, involved 284 cases with 151 deaths (53% case-fatality rate), traced to index cases with exposure to or unknown animal sources and amplified by close-contact transmission in a factory and hospitals. Concurrently, in near in (now ), 318 cases resulted in 280 deaths (88% case-fatality rate), initiated by a clinic worker handling contaminated needles and spreading via reused syringes in under-resourced medical settings. Serological and antigenic analyses distinguished these as virus variants (Sudan and Zaire subtypes), separate from but sharing filovirus traits, with no epidemiological link between the sites despite proximity. These early events underscored filoviruses' high lethality and nosocomial risks, with case-fatality rates varying by strain and outbreak conditions; investigations by teams from the , CDC, and local authorities highlighted the absence of but emphasized direct contact with infected fluids. Sporadic Marburg re-emergences followed, such as single cases in (1980, 1987), but no major epidemics until later decades, while Ebola's 1976 discoveries formalized the Filoviridae family in virological taxonomy based on shared genomic and ultrastructural features.

Major epidemics and geographic distribution

Filoviruses, primarily and viruses, have caused outbreaks almost exclusively in , with virus species concentrated in the humid rainforests of Central and , and associated with drier savanna-woodland ecotones extending from eastern to southern . Reston ebolavirus circulates in , notably the , where it has infected pigs and asymptomatically exposed humans without causing disease. and genetic detections suggest broader presence in bats across and potentially beyond, but human epidemics remain confined to , often near sites, forests, or caves linked to fruit bat habitats. Imported cases have occurred globally via travel, such as in the United States (1980) and (1967, 2008), but no secondary transmission outside . The inaugural filovirus outbreaks emerged in 1967 with in , , and , , stemming from imported African green monkeys; 31 cases resulted, with 7 deaths ( ~23%). virus debuted in 1976 across two simultaneous events: in Nzara, (284 cases, 151 deaths, CFR 53%), and in , (DRC; 318 cases, 280 deaths, CFR 88%). Subsequent smaller outbreaks included in (1982, 2 cases, 1 death) and DRC (1998-2000, 154 cases, 128 deaths, CFR 83%), alongside events like the 1995 Kikwit outbreak in DRC (315 cases, 254 deaths, CFR 81%) and 2000-2001 (425 cases, 224 deaths, CFR 53%). The most extensive epidemic unfolded from 2014 to 2016 in , driven by across , , and , tallying 28,616 cases and 11,310 deaths (CFR 40%), with spillover to , , and exported cases in and the . This event highlighted urban transmission risks and weak health infrastructure. Later outbreaks included the 2018-2020 Kivu province epidemic in DRC (3,481 cases, 2,299 deaths, CFR 66%), complicated by armed conflict, and smaller 2021-2022 events in and . Marburg's largest toll came in 2004-2005 (374 cases, 329 deaths, CFR 88%), followed by recent surges: 2023 (39 cases, 33 deaths, CFR 85%), 2023-2024 (64 cases, 15 deaths, CFR 23% as of October 2024), and 2025 (details limited, but declared ended March 2025 with fatalities).
OutbreakVirusLocationYearCasesDeathsCFR (%)
Marburg initial/196731723
Ebola Sudan197628415153
Ebola ZaireDRC197631828088
KikwitDRC199531525481
2000-200142522453
//2014-201628,61611,31040
DRC2018-20203,4812,29966
2004-200537432988
2023-2024641523
Cumulative filovirus deaths exceed 15,000 since 1976, predominantly from , with geographic clustering underscoring zoonotic spillovers from reservoirs amid and human encroachment. Variability in CFR reflects viral strain, healthcare access, and response efficacy, not inherent geographic factors.

Diagnostics and Surveillance

Laboratory detection methods

Laboratory detection of filoviruses, including genera such as and , primarily employs molecular methods due to their high sensitivity for detecting viral RNA in clinical specimens like blood, serum, or tissues during acute infection. (RT-PCR), often real-time quantitative RT-PCR (RT-qPCR), serves as the gold standard, targeting conserved genomic regions such as the (NP) gene to enable broad-spectrum detection across with limits of detection as low as 10-100 genome equivalents per reaction. These assays confirm infection within days of symptom onset, with viral loads peaking early in filovirus disease, and can be performed in 3 (BSL-3) or enhanced BSL-2 laboratories under strict protocols to minimize risk. Antigen detection assays, such as enzyme-linked immunosorbent assays (ELISAs) or rapid immunochromatographic tests, identify viral or directly in patient samples, offering quicker results than for field settings but with lower sensitivity, particularly in low-viremia cases. For Ebolavirus, cartridge-based systems like the Xpert Ebola Assay, which integrates RT-qPCR for and targets, provide results in approximately 90 minutes with a of about 142 copies per milliliter, facilitating point-of-care confirmation. Virus isolation via in Vero or other permissive cells remains confirmatory but is confined to BSL-4 facilities owing to the pathogens' transmission potential and lack of guarantees. Serological methods detect IgM or IgG antibodies via or indirect assays (IFA), useful for retrospective diagnosis or serological surveys but unreliable for acute-phase detection as seroconversion occurs 7-14 days post-symptom onset. Electron microscopy can visualize the characteristic filamentous of filoviruses in clinical samples, aiding definitive identification when combined with molecular data, though it is rarely used due to requirements for specialized equipment and expertise. Multiplex assays have been developed for simultaneous detection of filoviruses alongside other hemorrhagic fever agents, enhancing diagnostic efficiency in outbreak scenarios. All methods necessitate proper specimen handling, such as EDTA-preserved blood collected in at least 1-4 mL volumes, to preserve integrity.

Challenges in field epidemiology

Field epidemiology of filoviruses, such as and viruses, faces significant obstacles due to outbreaks occurring in remote, resource-limited regions of with inadequate infrastructure. In the 2014–2016 West Africa epidemic, the absence of robust systems delayed outbreak detection, contributing to over 28,000 cases and 11,000 deaths across , , and . Similar deficiencies persisted in the 2023 outbreak in , where limited field investigation capacity and few investigated alerts hindered timely response despite 16 confirmed cases and a 90% case-fatality rate. Logistical challenges exacerbate these issues, including poor transportation, communication breakdowns, and supply shortages for field teams. During Sierra Leone's 2014 Ebola response, case investigators encountered transportation deficits, data mismanagement, and fatigue from overburdened workloads, which impeded and containment efforts. Inadequate training and coordination among responders further compound delays, as seen in Guinea's 2014 outbreaks where field teams lacked equipment and , leading to fragmented . Community resistance, fueled by rumors, denial, and —such as fears of overreach or unproven treatments—often results in underreporting and non-compliance with measures. Biosafety risks to epidemiologists and healthcare workers pose additional hurdles, given filoviruses' high transmissibility via bodily fluids and potential for nosocomial spread. Human-to-human transmission chains, amplified by unsafe burial practices and handling, complicate in settings with low and cultural barriers to reporting. Delays in confirmation, due to challenges in sample transport under 4 conditions, further strain operations, as evidenced by prolonged detection times in resource-poor areas during multiple filovirus events. Ongoing efforts, such as Field Epidemiology Training Programs, aim to build capacity but remain limited by funding and political instability in endemic regions.

Prevention, Treatment, and Control

Biosafety protocols and containment

Filoviruses, including species such as Ebolavirus and Marburgvirus, are designated as Risk Group 4 agents by the Centers for Disease Control and Prevention (CDC), necessitating Biosafety Level 4 (BSL-4) containment for all manipulations of infectious materials due to their capacity for aerosol transmission, absence of licensed vaccines or therapies for certain strains, and potential to cause severe, life-threatening hemorrhagic fever with high lethality. BSL-4 laboratories, limited globally to facilities like the CDC's in Atlanta and the U.S. Army Medical Research Institute of Infectious Diseases in Frederick, Maryland, employ maximum containment to prevent any release, featuring HEPA-filtered air systems with directional airflow, self-closing and interlocking doors, and hands-free sinks for decontamination. Core protocols mandate the use of positive-pressure suits ventilated by external air supplies, operated within Class III cabinets or rigid glove boxes for all procedures to minimize exposure risks from injury, mucosal contact, , or , which represent the primary hazards. Personnel undergo extensive , baseline medical evaluations including where available (e.g., for ), and post-exposure monitoring; entry and exit involve chemical showers, UV decontamination, and clothing changes to ensure no viable egress. is autoclaved or chemically treated on-site, and all experiments require institutional committee approval with risk assessments tailored to filoviral stability in aerosols and fomites. For animal biosafety level 4 (ABSL-4) work, such as nonhuman challenge studies, facilities incorporate additional redundancies like isolated animal holding rooms and doubled filtration, as filoviruses replicate efficiently in mimicking human . In diagnostic contexts, the recommends inactivating suspect samples via gamma irradiation, heat (56°C for 30 minutes), or chemical fixation before transfer to BSL-2 or BSL-3 labs for or , but live remains strictly BSL-4. Incidents, such as the 2004 CDC exposure from a needlestick, underscore when followed, with no secondary transmissions reported under proper .

Vaccine development and efficacy

Vaccine development for Filoviridae has primarily focused on the most pathogenic species, (EBOV) and Marburg marburgvirus (MARV), accelerated by major outbreaks since the 2014–2016 West African Ebola epidemic that caused over 28,000 cases. Early efforts in the 1990s and 2000s emphasized recombinant viral vectors expressing viral glycoproteins (GP), with preclinical studies in nonhuman primates demonstrating protection against lethal challenge, though initial candidates faced immunogenicity and safety hurdles. The urgency of outbreaks prompted ring trials and accelerated regulatory pathways, leading to the first licensed EBOV , Ervebo (rVSVΔG-ZEBOV-GP), developed by Merck from a Canadian platform originating in the early 2000s. Ervebo, a live-attenuated vesicular stomatitis virus (VSV) vectored encoding EBOV GP, received FDA approval on December 19, 2019, following phase 1–3 showing robust immunogenicity and safety in over 15,000 participants. Its was established in the 2014–2016 ring vaccination cluster-randomized (PREVAIL II/), where indicated 100% effectiveness (95% CI: 64.8–100%) for preventing EBOV in individuals vaccinated more than 10 days post-exposure, with overall of 75% (95% CI: −15 to 100%) including early vaccinations; no vaccinated individuals developed confirmed EBOV in the main analysis cohort of 6,000+ rings. Observational data from the 2018–2020 of outbreak, involving over 90,000 vaccinations, corroborated high real-world effectiveness, with attack rates near zero in vaccinated contacts, though factors like outbreak dynamics limit without . Duration of immunity appears to wane after 1–2 years, prompting booster studies, and the elicits GP-specific and T-cell responses correlating with protection in challenge models. A second EBOV vaccine regimen, Zabdeno (Ad26.ZEBOV) followed by (MVA-BN-Filo) one month later—developed by Janssen and —received conditional marketing authorization in July 2020 and WHO prequalification, targeting broader filovirus coverage including , Bundibugyo ebolavirus, and MARV via multivalent expression. Phase 2/3 trials in 3,367 participants across , , and the demonstrated 98–100% seroresponse rates for EBOV antibodies post-Mvabea, with a favorable safety profile (serious adverse events in <1%), though remains inferred from bridging to Ervebo rather than direct outbreak trials. Neither fully protects against non-Zaire ebolaviruses in humans, with preclinical showing cross-protection limited by GP antigenic differences; ongoing multivalent platforms aim to address this gap. For MARV, no licensed vaccine exists as of October 2025, despite preclinical VSV-vectored candidates achieving 100% survival in macaque models post-single dose. Human trials lag, with phase 1 studies of DNA, VLP, and vectored vaccines confirming safety and immunogenicity but lacking efficacy endpoints due to absence of large outbreaks for field testing. In response to the 2024 Rwanda outbreak (66 cases, 15 deaths), an investigational Sabin VLP-based vaccine entered open-label phase 2 trials, alongside others like IAVI's candidates, evaluating safety in 500+ participants across US, Uganda, Kenya, and Rwanda sites starting April 2025. CEPI-funded pan-filovirus efforts, including stabilized GP designs, seek single-shot broad protection, but ethical constraints on placebo use in high-fatality settings necessitate adaptive trial designs relying on animal rule data for licensure. Overall, while EBOV vaccines have reduced case fatality in targeted deployments, gaps in coverage for other Filoviridae species, long-term durability, and pediatric data underscore ongoing development needs.

Antiviral therapies and supportive care

Specific antiviral therapies for Filoviridae infections remain limited, with approvals primarily for Ebola virus disease (EVD) caused by . Two (mAb) cocktails, REGN-EB3 (also known as Inmazeb) and mAb114 (Ebanga), have demonstrated efficacy in reducing mortality during the 2018–2020 of outbreak, with survival rates exceeding 70% in treated patients when administered early. These therapies target the viral glycoprotein to neutralize entry into cells, outperforming earlier candidates like ZMapp and in randomized trials. Broadly protective mAbs, such as MBP134AF, show promise against multiple ebolaviruses in animal models but lack human approval as of 2025. For Marburg virus disease (MVD) and other filoviruses like Sudan ebolavirus, no antivirals are approved by regulatory bodies such as the FDA or EMA. Experimental interventions, including remdesivir and mAb MBP091, were deployed under compassionate use during the 2024 Rwanda outbreak, though efficacy data remain preliminary and tied to expanded access protocols rather than controlled trials. Nucleoside analogs like galidesivir and favipiravir inhibit viral replication in preclinical Marburg models by targeting RNA polymerase, but human trials are ongoing without established survival benefits. Interferon-β has extended survival in nonhuman primate models of both Ebola and Marburg hemorrhagic fever by enhancing innate antiviral responses, yet clinical translation is hindered by logistical challenges in outbreak settings. Supportive care forms the cornerstone of filovirus , focusing on mitigating , , and secondary complications to improve outcomes independent of antiviral effects. Aggressive fluid resuscitation, electrolyte balancing, and hemodynamic monitoring prevent , which contributes to over 50% of fatalities in untreated cases. Symptom-directed interventions include antiemetics, analgesics, nutritional support via enteral feeding, and , with evidence from outbreak cohorts showing reduced case fatality rates when implemented early in Ebola Treatment Units. transfusions address and hemorrhage, though risks of transfusion-transmitted infections necessitate pathogen-reduced components in resource-limited areas. Overall, intensified supportive protocols during the 2014–2016 epidemic correlated with survival improvements from under 10% to over 20% in some centers, underscoring their causal role beyond any adjunctive antivirals.

Research Controversies and Future Risks

Debates on viral origins

The origins of viruses in the family Filoviridae are generally attributed to natural zoonotic spillovers from reservoirs, with phylogenetic and genomic evidence supporting an ancient evolutionary predating contact. Studies of endogenous filoviral elements in mammalian genomes indicate that these viruses have integrated into host DNA over millions of years, consistent with long-term co-evolution rather than recent introduction. For instance, paleoviral sequences in small mammals demonstrate extranuclear replication cycles akin to modern filoviruses, ruling out laboratory synthesis as a plausible origin. Empirical data from serological surveys and virus isolation strongly implicate fruit bats (family Pteropodidae) as the primary for pathogenic like and , with antibodies and viral RNA detected in such as Rousettus aegyptiacus across Africa and Asia. Outbreak investigations, including the 1976 Marburg outbreak linked to African green monkeys imported from and the 2014 Ebola epidemic tracing to handling in , reinforce spillover events from bats or intermediate hosts like , without evidence of engineered traits such as unnatural codon usage or restriction site patterns that might suggest manipulation. Debates within the focus primarily on the precise evolutionary timeline and dynamics rather than artificial origins. Recent genomic transfers analyses propose an ancient aquatic origin for the Filoviridae family, potentially in , with diversification into mammalian hosts occurring over , challenging earlier models of solely terrestrial emergence. Conflicting data on host interactions, such as the detection of non-pathogenic filoviruses like in European bats, highlight uncertainties in geographic lineages—e.g., vs. Asian clades like Reston ebolavirus—but phylogenetic trees consistently align with pressures, not gain-of-function alterations. Fringe claims of laboratory genesis, occasionally raised in non-peer-reviewed contexts, lack supporting genetic or epidemiological markers and contradict the sporadic, wildlife-associated pattern of outbreaks documented since 1967.

Gain-of-function research and biosecurity

Gain-of-function (GOF) research involving Filoviridae, such as Ebola and Marburg viruses, entails genetic modifications to enhance viral properties like transmissibility, virulence, or host range adaptation, primarily to predict evolutionary changes or inform countermeasures. Such experiments fall under U.S. oversight for dual-use research of concern (DURC) and pathogens with enhanced pandemic potential (PEPP), as filoviruses are classified as Risk Group 4 agents capable of causing severe, high-fatality hemorrhagic fevers with limited natural transmissibility but potential for laboratory enhancement. A 2014-2017 U.S. moratorium on certain GOF studies explicitly covered influenza, SARS/MERS coronaviruses, and extended risk assessments to filoviruses due to their pandemic potential if altered. Biosecurity protocols for filovirus research mandate Biosafety Level 4 (BSL-4) containment, involving positive-pressure suits, Class III biological safety cabinets, and rigorous decontamination to mitigate , , or exposure risks. Historical lab-acquired infections underscore these hazards: was first identified in 1967 following infections among European laboratory workers handling tissues from imported African green monkeys, with subsequent cases linked to needlestick injuries or improper handling in BSL facilities. Over decades, filoviruses have caused dozens of documented laboratory exposures worldwide, though fatality rates in treated cases have declined with improved supportive care; no confirmed community outbreaks from lab escapes have occurred, but the potential for enhanced strains amplifies containment failure consequences. Debates on filovirus GOF center on risk-benefit imbalances, with proponents arguing it aids and therapeutic development by modeling mutations, while critics, including epidemiologists, contend that empirical data from natural outbreaks suffice for and that accidental risks outweigh marginal gains, given filoviruses' inherent instability outside hosts. Enhanced oversight frameworks, such as the U.S. P3CO policy, require risk-benefit analyses and multi-agency reviews for proposed filovirus enhancements, prioritizing non-GOF alternatives like pseudoviruses for entry studies. Globally, only about 10 BSL-4 facilities handle live filoviruses, limiting scale but heightening concerns over insider threats or geopolitical misuse as bioweapons, despite technical challenges in stabilization.

Mutation potential and pandemic threats

Filoviruses, as negative-sense single-stranded viruses, exhibit mutation rates characteristic of viruses due to the error-prone nature of their , lacking proofreading mechanisms. Estimates for and Ravn viruses indicate an evolutionary rate of approximately 5.67 × 10⁻⁴ nucleotide substitutions per site per year, reflecting moderate variability within the family. During the 2014–2016 West African outbreak, the virus accumulated around 50 mutations in its first month of circulation, demonstrating rapid genomic under selective pressure. However, experimental studies reveal that while spontaneous mutation frequencies are high—comparable to other negative-sense viruses—many resulting variants are attenuated or non-viable, limiting adaptive potential for enhanced fitness. Despite this mutability, filoviruses have not historically triggered pandemics, primarily because their relies on direct contact with bodily fluids, yielding low basic reproduction numbers (R₀ estimates of 1.5–2.5 for virus disease), which facilitates containment despite case fatality rates exceeding 40% in many outbreaks. Spillover events from reservoirs occur infrequently, often as single introductions followed by limited human-to-human chains, with genomic analyses showing diverse viral populations in but bottlenecked diversity in epidemics. Naturally occurring , such as those in or genes during the 2013–2016 outbreak, have not observably increased transmissibility or in ways that evade control measures, though linked in non-structural proteins could theoretically replication . Pandemic threats from filoviruses remain theoretical, hinging on rare evolutionary leaps toward or reduced symptom severity to boost spread, events unobserved in sequenced strains despite extensive . Risk assessments rank filoviruses moderately for zoonotic spillover potential due to reservoir proximity in tropical regions, but interventions like rapid diagnostics and (e.g., rVSV-ZEBOV, 97% efficacious in ring vaccination trials) mitigate escalation. Emerging novel filoviruses, including apathogenic variants, underscore ongoing evolutionary dynamics in , yet no supports imminent global threats beyond localized epidemics; claims of heightened risk often stem from modeling rather than empirical outbreak data.

References

  1. [1]
    ICTV Virus Taxonomy Profile: Filoviridae - PMC - NIH
    Members of the family Filoviridae produce variously shaped, often filamentous, enveloped virions containing linear non-segmented, negative-sense RNA genomes ...
  2. [2]
    ICTV Virus Taxonomy Profile: Filoviridae 2024 - PMC - NIH
    Filoviridae is a family of negative-sense RNA viruses with genomes of about 13.1–20.9 kb that infect fish, mammals and reptiles.
  3. [3]
    Filoviruses - Medical Microbiology - NCBI Bookshelf - NIH
    Within the family there is a single genus, filovirus, and a separation into two sero-/genotypes, Marburg and Ebola. Ebola is subdivided into three subtypes, ...
  4. [4]
    Filoviruses: Ecology, Molecular Biology, and Evolution - PMC
    2. TAXONOMY ... The Filoviridae family is grouped within the order Mononegavirales, a diverse taxon of unsegmented negative-sense single-stranded RNA viruses.
  5. [5]
    Filovirus replication and transcription - PMC - PubMed Central
    The family Filoviridae is divided into two genera: Ebolavirus, with four distinct species (Zaire, Sudan, Côte d'Ivoire and Reston ebolavirus), and ...Missing: definition characteristics
  6. [6]
    Family: Filoviridae - ICTV
    Replication, The genome forms ribonucleoprotein complexes, which serve as templates for transcription and replication. Encapsidated antigenomic RNA is a ...
  7. [7]
    Filoviridae ~ ViralZone - Expasy
    The viral RNA dependent RNA polymerase binds the encapsidated genome at the leader region, then sequentially transcribes each genes by recognizing start and ...
  8. [8]
    Forty-Five Years of Marburg Virus Research - PMC
    It was not until 1976 that the now better-known member of the family, Ebola virus (EBOV), first emerged in Africa [6,7]. Shortly thereafter marburgviruses and ...
  9. [9]
    Current perspectives on the phylogeny of Filoviridae - PMC
    Filoviruses are large filamentous viruses, 80 nm in diameter and may vary in length from several hundred nm to as long as or longer than 1 μm. Their linear ...
  10. [10]
    Molecular Evolution of Viruses of the Family Filoviridae Based on 97 ...
    Viruses within Marburg marburgvirus and Sudan ebolavirus species can be traced back further and share most recent common ancestors approximately 700 and 850 ...
  11. [11]
    Proposal for a revised taxonomy of the family Filoviridae
    Virus taxonomy is the practice of describing, classifying, and naming viruses. Description involves the genetic, biological, and morphological characterization ...
  12. [12]
    Ebola | New England Journal of Medicine
    May 6, 2020 · The virologic taxon Filoviridae was defined in 1982 and subsequently amended regularly to accommodate changes. These amendments and the ...
  13. [13]
    Species List: Filoviridae - ICTV
    ICTV Report · Genus: Cuevavirus · Genus: Dianlovirus · Genus: Oblavirus · Genus: Orthoebolavirus · Genus: Orthomarburgvirus · Genus: Striavirus · Genus: Tapjovirus ...
  14. [14]
    Renaming of genera Ebolavirus and Marburgvirus to ...
    Aug 3, 2023 · Virus names remain unchanged and valid. Here, we outline the revised taxonomy of family Filoviridae as approved by the ICTV in April 2023.
  15. [15]
    Proposal for a revised taxonomy of the family Filoviridae
    Oct 30, 2010 · The taxonomy of the family Filoviridae (marburgviruses and ebolaviruses) has changed several times since the discovery of its members.The Genus Ebolavirus... · Marburg Virus And Ravn Virus... · Lloviu Virus Is A Novel...
  16. [16]
    Exploratory Temporal and Evolutionary Insights into the Filoviridae ...
    The Filoviridae family comprises enveloped viruses with filamentous morphology and a non-segmented, negative-sense single-stranded RNA (ssRNA−) genome. Their ...
  17. [17]
    Novel filoviruses: indication of a global threat or cause to reassess ...
    Aug 21, 2024 · Filoviruses such as Ebola virus are widely known as causative agents of severe human disease, although apathogenic filoviruses also exist.
  18. [18]
    Filoviruses: Scientific Gaps and Prototype Pathogen Recommendation
    Oct 18, 2023 · Filovirus genomes vary from approximately 15 to 19 kb in length. Common gene organizational structure is 3′-NP-VP35-VP40-GP-VP30-VP24-L-5′ but ...
  19. [19]
    Filoviridae - an overview | ScienceDirect Topics
    Filoviruses are notable for filamentous shapes with virions that range in length from 800 to 1200 nm.
  20. [20]
    Filoviruses: Scientific Gaps and Prototype Pathogen Recommendation
    Filoviruses are enveloped, negative-sense RNA viruses of the family Filoviridae in the order Mononegavirales that are named for the often-filamentous morphology ...Missing: characteristics | Show results with:characteristics
  21. [21]
    The lifecycle of the Ebola virus in host cells - PMC - NIH
    Transcription and replication: Viral mRNA is transcribed via the viral polymerase, and the viral proteins are subsequently translated. Replication of the viral ...
  22. [22]
    Assembly and transport of filovirus nucleocapsids - PMC
    Jul 28, 2022 · Filovirus replication cycle. Viral entry into target cells is initiated after attachment to the plasma membrane and is accomplished by ...
  23. [23]
    No exit: targeting the budding process to inhibit filovirus replication
    One potential target is the filovirus VP40 matrix protein, the key viral protein that drives the budding process, in part by mediating specific virus-host ...<|separator|>
  24. [24]
    Molecular Evolution of Viruses of the Family Filoviridae Based on 97 ...
    Here, detailed Bayesian coalescent phylogenetic analyses are performed on 97 whole-genome sequences, 55 of which are newly reported, to comprehensively examine ...
  25. [25]
    Genomic transfers help to decipher the ancient evolution of ...
    Sep 3, 2024 · The phylogenetic analysis based on unfiltered L-protein amino acid sequences from filoviruses revealed a distinctive TAPV-XILV grouping in the ...
  26. [26]
    Filoviruses are ancient and integrated into mammalian genomes
    Jun 22, 2010 · Phylogenetic and sequencing evidence from gene boundaries was consistent with integration of filoviruses in mammalian genomes. We detected ...Figure 2 · Figure 5 · Bioinformatics
  27. [27]
    Evolutionary maintenance of filovirus-like genes in bat genomes
    Nov 17, 2011 · We also estimated the age of filovirus VP35-like gene integrations and tested the phylogenetic hypotheses that there is a eutherian mammal ...
  28. [28]
  29. [29]
    Putative endogenous filovirus VP35-like protein potentially functions ...
    Oct 17, 2017 · Endogenous filovirus-like elements (EFLs) have been discovered in some mammalian genomes. However, their potential roles in ebolavirus infection ...
  30. [30]
    Filoviruses in Bats: Current Knowledge and Future Directions - PMC
    To date, there is evidence for filovirus infection in a total of 17 bat species for (Marburgvirus, Zaire ebolavirus, Reston ebolavirus, and Lloviu virus), but ...
  31. [31]
    Filoviruses and bats - PubMed
    Cumulative evidence suggests that bats are the most likely reservoir hosts of the filoviruses. Ecological investigations following Marburg virus disease ...
  32. [32]
    Marburgvirus in Egyptian Fruit Bats, Zambia - PMC - PubMed Central
    Epidemiologic evidence strongly suggests that Egyptian fruit bats (Rousettus aegyptiacus) are the primary natural reservoir of Marburgviruses. Entry into ...
  33. [33]
    Coordinated inflammatory responses dictate Marburg virus control ...
    Feb 28, 2024 · Egyptian rousette bats (ERBs) are the known reservoir of Marburg virus (MARV), a filovirus that causes deadly Marburg virus disease (MVD) in humans.
  34. [34]
    Deadly Marburg Virus Found in Sierra Leone Bats - CDC Archive
    Scientists have shown that the Egyptian rousette bat (Rousettus aegyptiacus) is the natural reservoir for Marburg virus, which means the bats can carry the ...<|separator|>
  35. [35]
    Asymptomatic Infection of Marburg Virus Reservoir Bats Is Explained ...
    Jan 25, 2021 · Egyptian rousette bats (ERBs, Rousettus aegyptiacus), cave-dwelling fruit bats common across sub-Saharan Africa and parts of the Middle East, ...
  36. [36]
    Modeling natural coinfection in a bat reservoir shows modulation of ...
    The Egyptian rousette bat (ERB) is a natural reservoir for Marburg virus (MARV; family Filoviridae), a putative reservoir for Sosuga virus (SOSV; family ...
  37. [37]
    Fruit bats as reservoirs of Ebola virus - Nature
    Nov 30, 2005 · We find evidence of asymptomatic infection by Ebola virus in three species of fruit bat, indicating that these animals may be acting as a reservoir for this ...
  38. [38]
    Ebola Virus Antibodies in Fruit Bats, Ghana, West Africa - PMC
    To the Editor: Fruit bats are the presumptive reservoir hosts of Ebola viruses (EBOVs) (genus Ebolavirus, family Filoviridae). When transmitted to humans ...
  39. [39]
    Assessing the Evidence Supporting Fruit Bats as the Primary ...
    We review current evidence and highlight that fruit bats may not represent the main, or the sole, reservoir.
  40. [40]
    Where is the elusive primary ebolavirus reservoir and how do we ...
    Apr 21, 2025 · Fruit bats from the group Pteropodidae are much stronger candidates for natural reservoirs in the context of Ebolavirus (Amman et al. 2017, ...Abstract · Search for reservoirs to date · Challenges to Ebolavirus...
  41. [41]
    Reservoir host studies of Lloviu virus: first isolation, sequencing and ...
    Aug 10, 2021 · Our data support the role of bats, specifically Miniopterus schreibersii as natural reservoirs for the LLOV filovirus in Europe. We also ...
  42. [42]
    Ecologic and Geographic Distribution of Filovirus Disease - PMC
    Filoviruses consist of two genera. The genus Marburgvirus contains one species, Lake Victoria marburgvirus, with several recognized strains, and Ebolavirus ...<|separator|>
  43. [43]
    Bats as putative Zaire ebolavirus reservoir hosts and their habitat ...
    Aug 31, 2020 · Different evidence suggests that bats are putative reservoir hosts and play a major role in the transmission cycle of these filoviruses.
  44. [44]
    Mapping the zoonotic niche of Marburg virus disease in Africa
    It is a zoonotic disease, with the Egyptian rousette (Rousettus aegyptiacus) identified as a reservoir host. Infection is suspected to result from contact ...
  45. [45]
    Marburg virus disease: origins, reservoirs, transmission and guidelines
    Jul 29, 2025 · ... Marburg virus is a zoonotic (animal borne) virus. Fruit bats (Rousettus aegyptii) are considered to be the natural host of the virus.Epidemiology · Symptoms · Transmission · Diagnosis
  46. [46]
    Marburg Virus Disease Emergence: An Update
    Mar 28, 2023 · Zoonotic transmission risk appears to peak biannually, corresponding to reproductive cycles and increased infection rates in juvenile bats upon ...
  47. [47]
    Bat-borne virus diversity, spillover and emergence - PMC
    Jun 11, 2020 · Antibody-mediated virus neutralization is not a universal mechanism of Marburg, Ebola, or Sosuga virus clearance in Egyptian rousette bats.
  48. [48]
    Predicting Ebola virus disease risk and the role of African bat birthing
    The study found that African bat birthing, especially fruit bat birthing, is correlated with Ebola outbreaks, and that bat birth-related terms improve models ...
  49. [49]
    How Ebola Disease Spreads - CDC
    Apr 25, 2024 · Infected animals can spread the virus to other animals through contact with infected body fluids or items contaminated by these fluids.
  50. [50]
    Ebola Virus Maintenance: If Not (Only) Bats, What Else? - MDPI
    Oct 9, 2018 · The EBOV maintenance host could shed viable viruses in the environment where bats could get infected by environmental exposure. The most likely ...4. Aerosol-Borne Route Of... · 5. Vector-Borne Route Of... · 11. Research Perspectives
  51. [51]
    Predictive Model for Estimating Annual Ebolavirus Spillover Potential
    Mar 19, 2025 · Forest changes, human population dynamics, and meteorologic conditions have been associated with zoonotic Ebolavirus spillover into humans. High ...
  52. [52]
    Human movement and transmission dynamics early in Ebola ...
    Many EVD outbreaks are triggered by a single spillover event followed by human-to-human transmission between close contacts. Most spillover events have been ...
  53. [53]
    Serological evidence of zoonotic filovirus exposure among ... - Nature
    May 16, 2024 · Human outbreaks typically arise following spillover of the pathogen from a natural reservoir or intermediate host. ... peer review of this work.
  54. [54]
    Transmission of Ebola Viruses: What We Know and What We Do Not ...
    Available evidence demonstrates that direct patient contact and contact with infectious body fluids are the primary modes for Ebola virus transmission.
  55. [55]
    Marburg Virus Disease - StatPearls - NCBI Bookshelf
    Sep 15, 2025 · [23] Human-to-human transmission can occur through contact with infected bodily fluids, eg, blood, saliva, sweat, urine, stool, or breast milk.
  56. [56]
    Ebola virus disease | Nature Reviews Disease Primers
    Feb 20, 2020 · EVD outbreaks typically start from a single case of probable zoonotic transmission, followed by human-to-human transmission via direct contact ...
  57. [57]
    Aerosol Transmission of Filoviruses - PMC - PubMed Central - NIH
    May 23, 2016 · During human EVD/filovirus disease outbreaks, human-to-human transmission likely occurs mainly through direct skin contact (including sexual ...
  58. [58]
    Ebola Virus Shedding and Transmission: Review of Current Evidence
    The major risk for human-to-human transmission is direct contact with infected body fluids from symptomatic patients with EVD [46–53]. The mean household ...Missing: peer- | Show results with:peer-
  59. [59]
    Ebola Virus Disease: Uniquely Challenging Among the Viral ...
    Once spillover has occurred, EBOV's human-to-human transmission makes containment challenging and poses significant nosocomial risk. Vaccines and targeted ...
  60. [60]
    Marburg Virus Disease: Epidemiology, Immune Responses, and ...
    May 12, 2025 · ... orthomarburgviruses [6]. Human-to-human transmission typically occurs through direct contact with the bodily fluids of infected individuals ...
  61. [61]
    Persistence and Sexual Transmission of Filoviruses - PMC
    During the 2014–2016 West African EVD epidemic, sporadic transmission events resulted in the initiation of new chains of human-to-human transmission.
  62. [62]
    Ebola Virus Transmission Initiated by Relapse of Systemic Ebola ...
    Mar 31, 2021 · Human-to-human transmission of Ebola virus (EBOV) typically occurs through direct contact with infectious blood or bodily fluids (e.g., semen or ...
  63. [63]
    Transmission dynamics and control of Ebola virus disease (EVD)
    Human outbreaks may stem from direct human exposure to fruit bats or intermediate infected hosts that primarily comprise non-human primates (that is, gorillas, ...
  64. [64]
    Ebola Disease Basics - CDC
    Apr 23, 2024 · People with Ebola disease may experience "dry" symptoms early in the course of illness. These symptoms may include fever, aches, pains, and fatigue.Signs and Symptoms · Outbreak History · Site Index · How It Spreads
  65. [65]
    About Marburg - CDC
    Sep 24, 2025 · The disease spreads through contact with infected animals or people. More Information. For Everyone Health Care Providers Public Health. A ...
  66. [66]
    Clinical Signs of Ebola Disease - CDC
    Jan 30, 2025 · Initial signs and symptoms are nonspecific and may include elevated body temperature or subjective fever, chills, myalgia, and fatigue. These ...
  67. [67]
    Clinical Overview of Marburg Virus Disease - CDC
    Jan 30, 2025 · The disease can lead to serious illness or death. Symptoms can appear suddenly and may include fever, rash, and severe bleeding.
  68. [68]
    Ebola disease - World Health Organization (WHO)
    Apr 24, 2025 · The symptoms of Ebola disease can be sudden and include fever, fatigue, malaise, muscle pain, headache and sore throat.
  69. [69]
    Fact Sheet: Is it COVID-19 or Marburg? - CDC
    Signs and symptoms of Marburg · Fever · Aches and pains, such as severe headache, muscle and joint pain, and stomach pain · Weakness and fatigue · Diarrhea and ...
  70. [70]
    Ebola Virus Disease - StatPearls - NCBI Bookshelf
    Mar 1, 2024 · Ebola virus disease presents with nonspecific symptoms, including fever, malaise, headache, diarrhea, and vomiting. A maculopapular rash is sometimes noted.
  71. [71]
    Sudan virus disease – A quick review - ScienceDirect
    Typical symptoms include fever, headache, abdominal pain, diarrhea, vomiting and myalgia. Hemorrhagic signs like melena, hematemesis and conjunctivitis are also ...Review Article · Clinical Manifestations And... · Vaccine Research And...
  72. [72]
    Signs and Symptoms of Ebola Disease - CDC
    Apr 23, 2024 · Wet symptoms · Nausea · Abdominal pain · Diarrhea · Vomiting. Other symptoms. Other symptoms may include chest pain, shortness of breath, ...
  73. [73]
    Basic Clinical and Laboratory Features of Filoviral Hemorrhagic Fever
    The filoviruses Marburg and Ebola cause fulminant hemorrhagic fever (HF) in humans, with high case fatality rates.Missing: peer- | Show results with:peer-
  74. [74]
    [PDF] Post-Ebola Syndrome, Sierra Leone - CDC
    Abdominal pain, vision loss, hear- ing loss, impotence, bleeding, psychological problems, and general weakness were listed qualitatively as symptoms of post- ...<|separator|>
  75. [75]
    Molecular mechanisms of Ebola pathogenesis - PubMed Central - NIH
    Ebola virus initially and preferentially infects monocytes, macrophages, and DCs. Infection of DCs impairs their maturation and suppresses type I IFN responses, ...Missing: peer- | Show results with:peer-
  76. [76]
    Filovirus pathogenesis and immune evasion: insights from Ebola ...
    Here we review the mechanisms deployed by filoviruses to block host innate immunity and discuss aspects of virus replication that promote disease.
  77. [77]
    Pathogenicity and virulence of Marburg virus - PMC - PubMed Central
    Apr 1, 2022 · Marburg virus primarily targets dendritic cells, monocytes, parenchyma cells at a liver, adrenocortical cells, and several lymphoid tissues.
  78. [78]
    Marburg virus pathogenesis – differences and similarities in humans ...
    Dec 30, 2019 · This review will compare various animal models to the available descriptions of human pathogenesis and aims to evaluate their effectiveness in modeling ...
  79. [79]
    Marburg virus disease - World Health Organization (WHO)
    Jan 20, 2025 · MVD was initially detected in 1967 after two simultaneous outbreaks in Marburg and Frankfurt in Germany, and in Belgrade, Serbia. These ...
  80. [80]
    Case fatality rate for Ebola disease, 1976-2022: A meta-analysis of ...
    We abstracted EBOD data from 1976 to 2022 for 16 countries and 42 outbreaks to conduct a meta-analysis. The pooled CFR was 60.6% (95% confidence interval (CI) ...
  81. [81]
    Emergence of Marburg virus: a global perspective on fatal outbreaks ...
    Past outbreaks have exhibited varying case fatality rates, ranging from 24% to 88%, contingent upon virus strain and case management (WHO, 2021a). According to ...
  82. [82]
    How severe and prevalent are Ebola and Marburg viruses? A ...
    Nov 25, 2016 · The fatality rates reported in different outbreaks ranged from 24–100%. In addition, sero-surveys conducted have shown different seropositivity ...Study Selection Criteria · Statistical Analysis · Literature Search Result<|separator|>
  83. [83]
    “Filoviruses”: a real pandemic threat? - PMC - PubMed Central
    Despite numerous efforts to identify the host reservoir(s), the transmission cycle of filoviruses between the animal host(s) and humans remains unclear. The ...
  84. [84]
    Distinguishing epidemiological features of the 2013–2016 West ...
    The case-fatality rate of 39.5 percent was much lower than the corresponding 65.9 percent rate computed as total deaths (1,595) among total cases (2,411) for ...Missing: variability | Show results with:variability
  85. [85]
    Marburg Virus Disease in Rwanda, 2024 — Public Health and ...
    Sep 10, 2025 · The case fatality rate in the outbreak was 23% (15 deaths among 66 patients). Remdesivir and the monoclonal antibody MBP091 were used under ...
  86. [86]
    Forty Years of Marburg Virus | The Journal of Infectious Diseases
    Forty years ago, in early August 1967, the first filovirus ever detected, Marburg virus, made its appearance in Europe, causing severe and often fatal ...
  87. [87]
    Marburg Hemorrhagic Fever — The Forgotten Cousin Strikes
    Between 1967 and 1998, Marburg virus infections were rare events, with only three incidences reported, each involving either a single case (Kenya, 1987) or an ...
  88. [88]
    Ebola haemorrhagic fever in Sudan, 1976 - PMC - NIH
    A large outbreak of haemorrhagic fever (subsequently named Ebola haemorrhagic fever) occurred in southern Sudan between June and November 1976.
  89. [89]
    Discovery and Description of Ebola Zaire Virus in 1976 and ...
    In 1976, the first cases of Ebola virus disease in northern Democratic Republic of the Congo (then referred to as Zaire) were reported.
  90. [90]
    Outbreak History | Ebola - CDC
    However, the case fatality rate was below 50% in this outbreak, compared to 80–90% found in earlier outbreaks caused by other orthoebolavirus strains, like ...Missing: variability | Show results with:variability
  91. [91]
    Marburg virus disease - World Health Organization (WHO)
    MVD was initially detected in 1967 after two simultaneous outbreaks ... Rwanda reports first-ever Marburg virus disease outbreak, with 26 cases confirmed.
  92. [92]
    Marburgvirus - an overview | ScienceDirect Topics
    The Marburg virus was first discovered in 1967, when it caused death in seven of 31 human cases in simultaneous outbreaks in Germany and Yugoslavia. This ...
  93. [93]
    Ecologic and geographic distribution of filovirus disease - PubMed
    We predicted that filovirus would occur across the Afrotropics: Ebola HF in the humid rain forests of central and western Africa, and Marburg HF in the drier ...
  94. [94]
    History of Marburg Outbreaks - CDC
    Jan 31, 2025 · Testing at CDC/UVRI identified a Marburg virus disease outbreak in the districts of Kabale, Ibanda, Mbarara, and Kampala over a three-week ...What To Know · Recent Marburg Outbreaks · History Of Marburg 1967-2024
  95. [95]
    Chapter 2: Major Ebola outbreaks in Africa | Mercy Corps
    In 2000 in Uganda, there were 425 Ebola cases and 224 deaths. The outbreak began in Gulu and spread to other districts.Where Did Ebola First Break... · 4. 2007 · 5. 2014 To 2016<|separator|>
  96. [96]
    Ebola virus disease - World Health Organization (WHO)
    The average EVD case fatality rate is around 50%. Case fatality rates have varied from 25% to 90% in past outbreaks. The first EVD outbreaks occurred in ...
  97. [97]
    Factsheet for health professionals about Marburg virus disease
    Oct 10, 2024 · Direct contact with the blood and other body fluids of infected people and animals or indirect contact with contaminated surfaces and materials ...The pathogen · Clinical features and sequelae · Epidemiology · Transmission
  98. [98]
    Outbreak of Marburg Virus Disease, Equatorial Guinea, 2023 - CDC
    Apr 3, 2025 · Wet symptoms were more frequently reported among probable cases, with 83% reporting diarrhea, although probable cases are representative of late ...
  99. [99]
    Marburg virus disease – Rwanda - World Health Organization (WHO)
    Oct 25, 2024 · As of 24 October 2024, a total of 64 Marburg virus disease cases, including 15 deaths (case fatality ratio (CFR) 23.4%), have been reported in Rwanda.Marburg Virus Disease... · Description Of The Situation · Who Advice<|separator|>
  100. [100]
    Ebola: A Hyperinflated Emergency - PMC - NIH
    Ebola has killed about 15,266 people globally since 1976. Most recently, 2,267 people have died in the Democratic Republic of the Congo (DRC).
  101. [101]
    Detection of all known filovirus species by reverse transcription ...
    In this study, a highly sensitive universal RT-PCR assay targeting the nucleo-protein (NP) gene of filoviruses was developed.
  102. [102]
    A high-throughput, polymerase-targeted RT-PCR for broad detection ...
    Jul 24, 2024 · A phylogenetic tree of 38 representative filoviruses L gene sequences, constructed using Clustal Omega/FastTree with 1,000 bootstrap replicates ...
  103. [103]
    VHF Specimen Collection | Viral Hemorrhagic Fevers (VHFs) - CDC
    May 10, 2024 · For adults, collect two 4 mL tubes of whole blood in a plastic tube preserved with EDTA. For pediatric patients, collect a minimum of 1 mL whole blood.Missing: detection | Show results with:detection
  104. [104]
    Pre-symptomatic diagnosis and treatment of filovirus diseases - PMC
    Filoviruses are virulent human pathogens which cause severe illness with high case fatality rates and for which there are no available FDA-approved vaccines ...
  105. [105]
    Diagnostics for filovirus detection: impact of recent outbreaks on the ...
    Feb 7, 2019 · The Centers for Disease Control and Prevention recommends that ELISA, PCR or virus isolation be used to diagnose MVD within a few days of ...<|separator|>
  106. [106]
    Diagnostic strategies for Ebola virus detection - The Lancet
    The Xpert Ebola Assay is an RT-qPCR test for detecting viral nucleoprotein and glycoprotein. The assay takes 90 min to produce results and has a limit of ...
  107. [107]
    [PDF] Cell Culture and Electron Microscopy for Identifying Viruses in ...
    Other useful laboratory methods for diagnosis of an unknown virus include serologic testing; IFA, histopath- ologic, and IHC assays; PCR; and sequencing.
  108. [108]
    [PDF] A Multiplex PCR/LDR Assay for the Simultaneous Identification of ...
    Sep 18, 2015 · A comprehensive molecular detection panel for high-throughput identification of these viruses, using a single cycling protocol and fluorescent.
  109. [109]
    Overview, Control Strategies, and Lessons Learned in the CDC ...
    Jul 8, 2016 · The lack of surveillance systems and other public health infrastructure impeded the ability of affected countries to effectively detect and ...Missing: obstacles | Show results with:obstacles
  110. [110]
    Overcoming Operational Challenges to Ebola Case Investigation in ...
    Major challenges included deficiencies in transportation and communication resources, low morale and fatigue among case investigators, mismanagement of data, ...
  111. [111]
    Challenges in controlling the Ebola outbreak in two prefectures in ...
    The study identified poor coordination mechanisms, inadequate training of human resources and lack of equipment and supplies to field teams and health ...Missing: obstacles | Show results with:obstacles
  112. [112]
    Two Obstacles in Response Efforts to the Ebola Epidemic in ... - NIH
    Denial and rumors are two major obstacles impairing the implementation of activities in response to the Ebola virus disease (EVD) epidemic.
  113. [113]
    Lessons from Ebola: improving infectious disease surveillance to ...
    Inadequate surveillance and/or reporting systems, a major issue for EVD in West Africa (3), may lead to delayed detection and substantial under-reporting.
  114. [114]
    Evaluation of Ebola virus disease surveillance system capability to ...
    Aug 2, 2023 · Ebola virus disease (EVD) surveillance systems in sub-Saharan Africa have been challenged with delays in detecting new outbreaks. The most ...Missing: obstacles | Show results with:obstacles
  115. [115]
    [PDF] Biosafety in Microbiological and Biomedical Laboratories—6th Edition
    The BMBL is an advisory document recommending best practices for safe work in biomedical labs, using protocol-driven risk assessment.Missing: Filoviridae | Show results with:Filoviridae
  116. [116]
    Evaluation of Perceived Threat Differences Posed by Filovirus Variants
    Research on infectious (“live”) filoviruses, which are classified as Risk Group 4 agents, requires Biosafety Level 4 (BSL-4) laboratories. Consequently ...
  117. [117]
    CDC LC Quick Learn: Recognize the four Biosafety Levels
    BSL-4, Continued. In addition to BSL-3 considerations, BSL-4 laboratories have the following containment requirements: Laboratory practices. Change clothing ...
  118. [118]
    Filoviruses – Ebola and Marburg Viruses | Office of Research
    Jun 12, 2019 · All work with infectious virus must be performed in BSL-4/ABSL-4 containment. PRIMARY HAZARDS: Accidental parenteral inoculation ...
  119. [119]
    Diagnostic testing for Ebola and Marburg virus diseases
    Dec 20, 2024 · The purpose of this interim guidance is to provide recommendations and operational considerations regarding the diagnosis of Ebola or Marburg virus disease.
  120. [120]
    Lab Advisory: Guidance for Marburg Virus Disease Specimen Testing
    May 25, 2023 · Clinical laboratories can safely perform routine diagnostic testing by following Standard Precautions for All Patient Care and the Bloodborne Pathogens ...
  121. [121]
    Managing Potential Laboratory Exposure to Ebola Virus by Using a ...
    One-sentence summary for table of contents: Recommendations are needed for management of potential laboratory exposure to a Biosafety Level 4 pathogen.
  122. [122]
    Development of Pandemic Vaccines: ERVEBO Case Study - PMC
    This review describes the development program of this EBOV vaccine, summarizes what is known about safety, immunogenicity, and efficacy.
  123. [123]
    Translational success of fundamental virology: a VSV-vectored ...
    Feb 2, 2024 · The history of the development of a safe and effective Ebola vaccine underscores the importance of fundamental virology and represents a major ...<|separator|>
  124. [124]
    rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious ...
    Feb 28, 2025 · Preclinical studies conducted prior to the 2014–2016 EBOV outbreak consistently demonstrated the efficacy of rVSVΔG-based vaccines in protecting ...
  125. [125]
    Ebola Vaccine Product Information - CDC
    Jan 30, 2025 · Efficacy. Clinical efficacy of the vaccine was supported by a randomized cluster vaccination study during the 2014–2016 outbreak in Guinea.
  126. [126]
    Protocol for a phase 3 trial to evaluate the effectiveness and safety of ...
    Mar 8, 2022 · This is the first large-scale trial designed to measure effectiveness of a two-dose Ebola vaccine through open label delivery to general ...
  127. [127]
    Use of Ebola Vaccines — Worldwide, 2021–2023 | MMWR - CDC
    Apr 25, 2024 · ERVEBO was shown to be safe and effective during clinical trials and has likely played an important role in limiting Ebola morbidity and ...
  128. [128]
    Immunogenicity and safety of Ebola virus vaccines in healthy adults
    Clinical development of Ebola virus vaccines (EVV) was accelerated by the West African Ebola virus epidemic which remains the deadliest in history.
  129. [129]
    Ebola virus disease vaccines - World Health Organization (WHO)
    Oct 16, 2025 · The Zabdeno and Mvabea vaccine was studied in a total of 3 367 adults, adolescents and children who participated in 5 clinical studies conducted ...
  130. [130]
    Filovirus vaccines as a response paradigm for emerging infectious ...
    Oct 11, 2024 · This review article summarizes the current filovirus vaccines in preclinical macaque studies and human clinical trials and discusses the most promising recent ...
  131. [131]
    Therapeutic advances in Marburg virus disease - PubMed Central
    Mar 28, 2025 · This work explored ongoing studies on the recent vaccine developments and experimental therapies, such as a recombinant vesicular stomatitis virus (VSV)-based ...
  132. [132]
    How Rwanda mounted a research response with an investigational ...
    Aug 1, 2025 · The response was notable for the rapid deployment of an investigational Marburg vaccine in an open-label Phase 2 clinical trial (pactr.samrc.ac.
  133. [133]
    Sabin Begins Marburg Vaccine Trial in U.S.
    Apr 16, 2025 · The Sabin Vaccine Institute has launched a multi-site Phase 2 clinical trial in the US for its Marburg vaccine candidate, administering doses to the first ...Missing: efficacy | Show results with:efficacy
  134. [134]
    CEPI backs new research into vaccines against multiple deadly ...
    Oct 5, 2025 · Researchers will test new vaccines that could provide all-in-one protection against viruses including Zaire Ebolavirus, Marburg and Sudan ...Missing: discoveries 2020-2025
  135. [135]
    Rational design of next-generation filovirus vaccines with ... - bioRxiv
    Mar 2, 2025 · In this study, we evaluate a general strategy for stabilizing glycoprotein (GP) structures of Ebola, Sudan, and Bundibugyo ebolaviruses and Ravn marburgvirus.
  136. [136]
    One-for-one or one-for-all? Considerations for filovirus vaccine ...
    Apr 14, 2025 · Substantial improvements have been made to the disease outcomes of filovirus-infected people in Africa since the West African epidemic.Missing: Filoviridae | Show results with:Filoviridae
  137. [137]
    Monoclonal Antibody Therapy for Ebola Virus Disease
    Nov 27, 2019 · This latest trial shows unequivocally the role that monoclonal antibodies can play in reducing deaths from EVD. This raises the question of ...
  138. [138]
    Ebola-specific therapeutic antibodies from lab to clinic: The example ...
    The underlying efficacy that drives the approval success of mAbs is reflected in sales. By 2019, of the top 20 therapeutics by sales, 9 are antibodies ...Ebola-Specific Therapeutic... · 1. Historical Perspective · 2. Clinical Perspective
  139. [139]
    A review of broadly protective monoclonal antibodies to treat Ebola ...
    Here, we review viral glycoprotein-targeting mAbs that have proved their broader protective efficacy in animal models. MBP134AF, the most advanced of these new- ...
  140. [140]
    Novel antiviral approaches for Marburg: a promising therapeutics in ...
    Apr 24, 2024 · Galidesivir and Favipiravir are antiviral drugs demonstrating potential in treating Marburg virus infection through distinct mechanisms.<|separator|>
  141. [141]
  142. [142]
    Caring for Critically Ill Patients with Ebola Virus Disease ...
    Aug 20, 2014 · The most important aspect of supportive care is aggressive prevention of intravascular volume depletion, correcting profound electrolyte ...
  143. [143]
    Filovirus Hemorrhagic Fever Outbreak Case Management
    Supportive care, the current standard for FHF treatment, consists of oral medication, oral fluid rehydration, nutritional supplementation, and psychosocial ...
  144. [144]
    Treatment-focused Ebola Trials, Supportive Care and Future of ...
    Supportive care guidelines for filovirus infection should be defined and established as standard of care for treatment of EVD. Keywords: Clinical Trials; Ebola ...
  145. [145]
    Filoviruses are ancient and integrated into mammalian genomes
    Jun 22, 2010 · Our findings indicate that filovirus infections have been recorded as paleoviral elements in the genomes of small mammals despite extranuclear replication.Missing: debate | Show results with:debate
  146. [146]
    Filovirus infections in - AVMA Journals
    May 1, 2009 · The focus of this review is the zoonotic nature of the filoviruses. Filovirus Pathobiology. Ebola virus and MARV, members of the family ...
  147. [147]
    Genomic transfers help to decipher the ancient evolution of ... - bioRxiv
    Nov 29, 2023 · Although several filoviruses are dangerous human pathogens, there is conflicting evidence regarding their origins and interactions with ...Introduction · Results · DiscussionMissing: debate | Show results with:debate
  148. [148]
    Isolation and genome characterization of Lloviu virus from Italian ...
    Jul 13, 2023 · Recent studies with recombinant and wild-type LLOV isolates confirmed the zoonotic nature of the virus in vitro. We examined bat samples from ...Results · Materials Methods · Llov Rna Detection And...
  149. [149]
    Potential Benefits of Gain-of-Function Research - NCBI - NIH
    GoF research is helpful for adapting viruses to growth in culture and for developing essential animal models for emerging pathogens.Missing: Marburg | Show results with:Marburg
  150. [150]
    Gain-of-Function Research: Balancing Science and Security
    Apr 12, 2023 · Gain-of-Function Research: Balancing Science and Security. Gain ... Ebola, and influenza—would be carefully evaluated for biosecurity risks.
  151. [151]
    [PDF] Implementation Guidance for the United States Government Policy ...
    May 6, 2024 · The purpose of the United States Government Policy for Oversight of Dual Use Research of. Concern and Pathogens with Enhanced Pandemic ...
  152. [152]
    [PDF] UCLA Policy 995: Dual Use Research of Concern (DURC) and ...
    Mar 7, 2025 · Dual use research refers to research conducted for legitimate purposes that can be utilized for ... • Filoviruses o Ebola viruses o Marburg ...
  153. [153]
    Feds lift gain-of-function research pause, offer guidance - CIDRAP
    Dec 19, 2017 · The National Institutes of Health (NIH) today lifted a 3-year moratorium on funding gain-of-function (GOF) research on potential pandemic viruses such as avian ...<|separator|>
  154. [154]
    NIH lifts 3-year ban on funding risky virus studies | Science | AAAS
    Concerns over so-called "gain-of-function" (GOF) studies that make pathogens more potent or likely to spread in people erupted in 2011, when Kawaoka's team ...
  155. [155]
    Emergent Risk Group-4 (RG-4) Filoviruses: A paradox in progress
    Aug 31, 2023 · Filoviruses, categorized as World Health Organization (WHO) Risk Group 4 (RG-4) pathogens, represent significant global health risks due to ...
  156. [156]
    Defense against filoviruses used as biological weapons
    Work with all filovirus species requires Biosafety Level 4 (BSL-4) “space suit” containment. Since the filoviruses were first discovered in 1967, only 10 ...Introduction · Filoviruses As Biowarfare... · Ebola And Marburg Disease In...<|control11|><|separator|>
  157. [157]
    The Elusive Payoff of Gain-of-Function Research - Undark Magazine
    Dec 23, 2024 · In short, Sutton was intending to give the virus a “gain of function,” or GOF, that might improve its transmissibility.
  158. [158]
    Little to be gained through 'gain-of-function' research, says expert
    Jan 9, 2025 · According to Marc Lipsitch, professor of epidemiology at Harvard TH Chan School of Public Health, the risks of this research are not worth the potential gains.
  159. [159]
    Why Do Exceptionally Dangerous Gain-of-Function Experiments in ...
    This chapter makes the case against performing exceptionally dangerous gain-of-function experiments that are designed to create potentially pandemic and novel ...
  160. [160]
    Oversight of Gain-of-Function Research with Pathogens: Issues for ...
    Jul 1, 2025 · Current US policy focuses on GOF research that involves altered or enhanced pathogens with the potential to cause a pandemic.Missing: Ebola Marburg
  161. [161]
    Efforts to Define Dual-Use Research of Bioterrorism Concern
    The U.S. National Science Advisory Board for Biosecurity (NSABB) calls such research “dual-use research of concern” (DURC) and defines it as: ... Filovirus ...
  162. [162]
    Ebola virus mutating rapidly as it spreads - Nature
    Aug 28, 2014 · The virus amassed 50 mutations during its first month, the researchers found. They say there is no sign that any of these mutations have ...Missing: potential pandemic
  163. [163]
    Study Shows High Frequency of Spontaneous Mutation in Ebola Virus
    Essentially, Ebola virus has the potential to evolve rapidly but the genetic changes result in viruses that are weakened or not viable. Due to the ...Missing: pandemic threat
  164. [164]
    Ranking the risk of animal-to-human spillover for newly ... - PNAS
    Apr 5, 2021 · We developed an open-source risk assessment to systematically evaluate novel wildlife-origin viruses in terms of their zoonotic spillover and spread potential.
  165. [165]
    Linked Mutations in the Ebola Virus Polymerase Are Associated with ...
    Mar 22, 2023 · During the2013 to 2016 Western Africa EBOV outbreak, several mutants emerged, with changes in the genes of nucleoprotein (NP), glycoprotein (GP ...
  166. [166]
    Interventions to Reduce Risk for Pathogen Spillover and Early ...
    Feb 15, 2023 · The risk of pathogen spillover and early disease spread among domestic animals and humans, however, can be reduced by stopping the clearing and ...<|control11|><|separator|>